アメリカの血漿交換療法(TPE)市場予測(~2021)

◆英語タイトル:U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021
◆商品コード:MD-4451
◆発行会社(調査会社):MarketsandMarkets
◆発行日:2016年7月19日
◆ページ数:91
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:米国
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥644,100見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 Million by 2021, growing at a CAGR of 11% to 12% during the forecast period. The growing prevalence of neurological diseases; increasing adoption of TPE procedures in rare disorders such as Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Neuromylitis Optica, Thrombotic Thrombocytopenic Purpura (TTP), Cryoglobulinaemia; and growing awareness about increasing the clinical response rate of TPE procedures in various diseases in the U.S. are driving the growth of this market. However, factors such as high cost of therapeutic plasma exchange procedures, lack of awareness about the TPE process, lack of skilled professionals, and risks associated with therapeutic plasma exchange procedures are restraining the growth of the U.S. therapeutic plasma exchange market to a certain extent.
In this study, the U.S. therapeutic plasma exchange (TPE) market is segmented on the basis of indications. The research report discusses the total number of patients undergoing TPE procedures, average number of procedures per patient, and total number of TPE procedures performed in the U.S. (2015).

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders.

In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

The major players in the U.S. therapeutic plasma exchange market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

【レポートの目次】

Table of Contents

1 Introduction
1.1 Objectives and Scope
1.2 Research Methodology
1.3 Market Estimation Methodology
1.4 Primary Research Methodology
1.5 Primary Respondent Profile

2 Key Insights

3 Therapeutic Plasma Exchnage Market, By Indication
3.1 Guillain-Barré Syndrome (GBS)
3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3.3 Myasthenia Gravis (MG)
3.4 Multiple Sclerosis (MS)
3.5 Neuromyelitis Optica (NMO)
3.6 Thrombotic Thrombocytopenic Purpura (TTP)
3.7 Cryoglobulinemia
3.8 Multiple Myeloma (MM)
3.9 Waldenstrom Macroglobulinemia (WM)
3.10 Hemolytic Uremic Syndrome (HUS)
3.11 Anti-GBM Disease (Goodpasture’s Syndrome)
3.12 Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis)
3.13 Post-Renal Transplant Rejection
3.14 Familial Hypercholesterolemia (Homozygous)
3.15 Anca-Associated Vasculitis

4 Appendix
4.1 Epidemiology Data
4.2 Industry Speaks
4.3 Details of Primary Respondents
4.4 Available Customizations
4.4.1 Company Profiles
4.4.1.1 Fresenius Se & Co. KGAA
4.4.1.2 B. Braun Melsungen AG
4.4.1.3 Baxter International Inc
4.4.1.4 Asahi Kasei Medical Co., Ltd.
4.4.1.5 Terumo BCT, Inc.
4.4.1.6 Haemonetics Corporation
4.4.1.7 Kawasumi Laboratories, Inc.
4.4.1.8 Hemacare Corporation
4.5 Knowledge Store: Marketsandmarkets’ Subscription Portal

List of Tables (55 Tables)

Table 1 Data Model
Table 2 U.S.: Therapeutic Plasma Exchange Market Size, By Indication, 2014–2021 (USD Million)
Table 3 U.S.: Therapeutic Plasma Exchange Market– Patient Population and Number of Procedures
Table 4 U.S. Disease Statistics: Acute Inflammatory Demyelinating Polyneuropathy
Table 5 Treatment Guidelines & Protocols : Guillain-Barré Syndrome (GBS)
Table 6 Epidemiology : Guillain-Barré Syndrome (GBS)
Table 7 U.S. Disease Statistics: Chronic Inflammatory Demyelinating Polyneuropathy
Table 8 Treatment Guidelines & Protocols : Chronic Inflammatory Demyelinating Polyneuropathy
Table 9 Epidemiology : Chronic Inflammatory Demyelinating Polyneuropathy
Table 10 U.S. Disease Statistics: Myasthenia Gravis (MG)
Table 11 Treatment Guidelines & Protocols : Myasthenia Gravis (MG)
Table 12 Epidemiology : Myasthenia Gravis (MG)
Table 13 U.S. Disease Statistics: Multiple Sclerosis (MS)
Table 14 Treatment Guidelines & Protocols : Multiple Sclerosis (MS)
Table 15 Epidemiology : Multiple Sclerosis (MS)
Table 16 U.S. Disease Statistics: Neuromyelitis Optica (NMO)
Table 17 Treatment Guidelines & Protocols : Neuromyelitis Optica (NMO)
Table 18 Epidemiology : Neuromyelitis Optica (NMO)
Table 19 U.S. Disease Statistics: Thrombotic Thrombocytopenic Purpura (TTP)
Table 20 Treatment Guidelines & Protocols : Thrombotic Thrombocytopenic Purpura (TTP)
Table 21 Epidemiology : Thrombotic Thrombocytopenic Purpura (TTP)
Table 22 U.S. Disease Statistics: Cryoglobulinemia
Table 23 Treatment Guidelines & Protocols : Cryoglobulinemia
Table 24 Epidemiology : Cryoglobulinemia
Table 25 U.S. Disease Statistics: Multiple Myeloma (MM)
Table 26 Treatment Guidelines & Protocols : Multiple Myeloma (MM)
Table 27 Epidemiology : Multiple Myeloma (MM)
Table 28 U.S. Disease Statistics: Waldenstrom Macroglobulinemia (WM)
Table 29 Treatment Guidelines & Protocols : Waldenstrom Macroglobulinemia (WM)
Table 30 Epidemiology : Waldenstrom Macroglobulinemia (WM)
Table 31 U.S. Disease Statistics: Hemolytic Uremic Syndrome (HUS)
Table 32 Treatment Guidelines & Protocols : Hemolytic Uremic Syndrome (HUS)
Table 33 Epidemiology : Hemolytic Uremic Syndrome (HUS)
Table 34 U.S. Disease Statistics: Anti-GBM Disease (Goodpasture’s Syndrome)
Table 35 Treatment Guidelines & Protocols : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 36 Epidemiology : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 37 U.S. Disease Statistics: Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis
Table 38 Treatment Guidelines & Protocols : Wegener’s Granulomatosis
Table 39 Epidemiology : Wegener’s Granulomatosis
Table 40 U.S. Disease Statistics: Post-Renal Transplant Rejection
Table 41 Treatment Guidelines & Protocols : Post-Renal Transplant Rejection
Table 42 Epidemiology : Post-Renal Transplant Rejection
Table 43 U.S. Disease Statistics: Familial Hypercholesterolemia (Homozygous)
Table 44 Treatment Guidelines & Protocols : Familial Hypercholesterolemia (Homozygous)
Table 45 Epidemiology : Familial Hypercholesterolemia (Homozygous)
Table 46 U.S. Disease Statistics: Anca-Associated Vasculitis
Table 47 Epidemiology Data
Table 48 Details of Primary Respondents (1/8)
Table 49 Details of Primary Respondents (2/8)
Table 50 Details of Primary Respondents (3/8)
Table 51 Details of Primary Respondents (4/8)
Table 52 Details of Primary Respondents (5/8)
Table 53 Details of Primary Respondents (6/8)
Table 54 Details of Primary Respondents (7/8)
Table 55 Details of Primary Respondents (8/8)


List of Figures (10 Figures)

Figure 1 Research Methodology
Figure 2 Market Estimation Methodology
Figure 3 Primary Research Methodology
Figure 4 Respondent Profile, By Organization
Figure 5 Respondent Profile, By Designation
Figure 6 Industry Speaks (1/3)
Figure 7 Industry Speaks (2/3)
Figure 8 Industry Speaks (3/3)
Figure 9 Marketsandmarkets Knowledge Store Snapshot
Figure 10 Marketsandmarkets Knowledge Store: Healthcare Industry Snapshot

【レポートのキーワード】

治療的血漿交換、血漿交換療法、アメリカ、疾患、医療

★調査レポート[アメリカの血漿交換療法(TPE)市場予測(~2021)]販売に関する免責事項
★調査レポート[アメリカの血漿交換療法(TPE)市場予測(~2021)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆